205 related articles for article (PubMed ID: 37166279)
1. High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
Vias M; Morrill Gavarró L; Sauer CM; Sanders DA; Piskorz AM; Couturier DL; Ballereau S; Hernando B; Schneider MP; Hall J; Correia-Martins F; Markowetz F; Macintyre G; Brenton JD
Elife; 2023 May; 12():. PubMed ID: 37166279
[TBL] [Abstract][Full Text] [Related]
2. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
3. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD
J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581
[TBL] [Abstract][Full Text] [Related]
4. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
5. Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro.
Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
7. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
8. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
11. Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G; Goranova TE; De Silva D; Ennis D; Piskorz AM; Eldridge M; Sie D; Lewsley LA; Hanif A; Wilson C; Dowson S; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Paul J; Supernat A; Millan D; Hoyle A; Bryson G; Nourse C; Mincarelli L; Sanchez LN; Ylstra B; Jimenez-Linan M; Moore L; Hofmann O; Markowetz F; McNeish IA; Brenton JD
Nat Genet; 2018 Sep; 50(9):1262-1270. PubMed ID: 30104763
[TBL] [Abstract][Full Text] [Related]
12. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
[TBL] [Abstract][Full Text] [Related]
13. Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity.
Sun T; Zhang Z; Tian L; Zheng Y; Wu L; Guo Y; Li X; Li Y; Shen H; Lai Y; Liu J; Cui H; He S; Ren Y; Yang G
J Adv Res; 2023 Jun; 48():213-225. PubMed ID: 36038111
[TBL] [Abstract][Full Text] [Related]
14. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
[TBL] [Abstract][Full Text] [Related]
15. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
16. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
17. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract][Full Text] [Related]
18. Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.
Martins FC; Couturier DL; de Santiago I; Sauer CM; Vias M; Angelova M; Sanders D; Piskorz A; Hall J; Hosking K; Amirthanayagam A; Cosulich S; Carnevalli L; Davies B; Watkins TBK; Funingana IG; Bolton H; Haldar K; Latimer J; Baldwin P; Crawford R; Eldridge M; Basu B; Jimenez-Linan M; Mcpherson AW; McGranahan N; Litchfield K; Shah SP; McNeish I; Caldas C; Evan G; Swanton C; Brenton JD
Nat Commun; 2022 Oct; 13(1):6360. PubMed ID: 36289203
[TBL] [Abstract][Full Text] [Related]
19. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
[TBL] [Abstract][Full Text] [Related]
20. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]